Table 2. . Summary of reported immune checkpoint inhibitors experience in patients with solid organ transplants.

Patient	Study	Transplant	Cancer	ICI agent	Rejection (Y/N)	Immunosuppression prior to ICI	Immunosuppression during ICI treatment	Outcome
1	Lipson et al.	Kidney	MM	Ipilimumab	N	Prednisone/tacrolimus	Prednisone	Response
2	Lipson et al.	Kidney	MM	Ipilimumab	N	Prednisone/tacrolimus/mycophenolate	Prednisone	Response
3	Ranganath et al.	Liver	MM	Ipilimumab	N	Tacrolimus	Tacrolimus	POD
4	Morales et al.	Liver	MM	Ipilimumab	N	Rapamycin/mycophenolate	Rapamycin	Response
5	Jose et al.	Kidney	Metastatic Choroidal Melanoma	Ipilimumab	Y	Tacrolimus	Prednisolone	Not Reported
6	Herz et al.	Kidney	MM	Ipilimumab	N	Prednisone/tacrolimus	Prednisone/tacrolimus	POD
Nivolumab (after ipilimumab)
7	Spain et al.	Kidney	MM	Ipilimumab	N	Prednisone/tacrolimus	Prednisone	POD
Nivolumab (after ipilimumab)	Y	Prednisone	Response
8	Alhamad et al.	Kidney	Metastatic SCC of skin	Ipilimumab	N	Cyclosporine/prednisone	Prednisone	POD
Nivolumab (after ipilimumab)	Y	Prednisone	Not reported
9	Qin et al.	Heart	MM	Ipilimumab	N	Tacrolimus	Tacrolimus	POD
Pembrolizumab (after ipilimumab)
10	Grant et al.	Heart	MM	Pembrolizumab	N	Tacrolimus/mycophenolate	Tacrolimus/mycophenolate	POD
11	Ong et al.	Kidney	MM	Nivolumab	Y	Prednisone/tacrolimus/mycophenolate	Prednisone	Response
12	Lipson et al.	Kidney	Metastatic SCC of skin	Pembrolizumab	Y	Cyclosporine/prednisone	Prednisone	Response
13	Owonikoko et al.	Heart	Metastatic SCC of skin	Nivolumab	Y	Tacrolimus/sirolimus	Prednisone/tacrolimus	Not reported
14	Barnett et al.	Kidney	Metastatic Adenocarcinoma of the Duodenum	Nivolumab	N	Prednisone/tacrolimus/mycophenolate	Prednsione/sirolimus	Response
15	Boils et al.	Kidney	Stage IV NSCLC	Nivolumab	Y	Cyclosporine/prednisone	Reduced dose cyclosporine/prednisone	Not reported
16	Kittai et al. [68]	Kidney	Metastatic SCC of skin	Nivolumab	N	Prednisone/tacrolimus/mycophenolate	Prednisone/sirolimus	Response
17	Kittai et al.	Orthotopic Heart Transplant	Stage IV NSCLC	Nivolumab	N	Prednisone/cyclosporine/mycophenolate	Reduced dose cyclosporine/reduced dose mycophenolate	Response

ICI: Immune checkpoint inhibitor; MM: Metastatic melanoma; N: No; NSCLC: Non-small-cell lung cancer; POD: Progression of disease; SCC: Squamous cell carcinoma; Y: Yes.